Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Cost-effectiveness of TNF-α inhibition in active ankylosing spondylitis: a systematic appraisal of the literature.

Kirchhoff TD, Mittendorf T, Schmidt RE, Jablonka A, Merkesdal S.

Expert Rev Pharmacoecon Outcomes Res. 2012 Jun;12(3):307-17. doi: 10.1586/erp.12.19. Review.

PMID:
22812555
2.

TNF-blocking therapy in rheumatoid arthritis and ankylosing spondylitis: why is cost-effectiveness a major issue?

Merkesdal S, Zeidler H.

Curr Rheumatol Rep. 2005 Aug;7(4):254-8. Review. No abstract available.

PMID:
16045826
3.

Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides.

Braun J, van der Heijde D.

Expert Opin Investig Drugs. 2003 Jul;12(7):1097-109. Review.

PMID:
12831346
4.

Treatment of ankylosing spondylitis and other spondyloarthritides.

Braun J, Baraliakos X.

Curr Opin Rheumatol. 2009 Jul;21(4):324-34. doi: 10.1097/BOR.0b013e32832c6674. Review.

PMID:
19461519
5.

Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.

Nguyen CM, Bounthavong M, Mendes MA, Christopher ML, Tran JN, Kazerooni R, Morreale AP.

Pharmacoeconomics. 2012 Jul 1;30(7):575-93. doi: 10.2165/11594990-000000000-00000. Review. Erratum in: Pharmacoeconomics. 2012 Nov 1;30(11):1096.

PMID:
22640174
6.

Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis.

De Keyser F, Baeten D, Van den Bosch F, Kruithof E, Verbruggen G, Mielants H, Veys E.

Drugs. 2004;64(24):2793-811. Review.

PMID:
15563249
7.

Socioeconomic consequences of ankylosing spondylitis.

Boonen A.

Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S23-6. Review.

PMID:
12463442
8.

A systematic literature review of the economic impact of ankylosing spondylitis.

Palla I, Trieste L, Tani C, Talarico R, Cortesi PA, Mosca M, Turchetti G.

Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S136-41. Epub 2012 Oct 16. Review.

PMID:
23072824
9.

Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis.

Davis JC Jr.

Semin Arthritis Rheum. 2005 Feb;34(4):668-77. Review.

PMID:
15692960
10.

Biologic therapies in the spondyloarthritis: new opportunities, new challenges.

Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J.

Curr Opin Rheumatol. 2003 Jul;15(4):394-407. Review.

PMID:
12819466
11.

Management and treatment of ankylosing spondylitis.

Zochling J, Braun J.

Curr Opin Rheumatol. 2005 Jul;17(4):418-25. Review.

PMID:
15956838
12.

A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis.

Boonen A.

Nat Clin Pract Rheumatol. 2006 Oct;2(10):546-53. Review.

PMID:
17016480
13.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
14.

Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives?

Kiltz U, Heldmann F, Baraliakos X, Braun J.

Curr Opin Rheumatol. 2012 May;24(3):252-60. doi: 10.1097/BOR.0b013e3283524b82. Review.

PMID:
22450391
15.

[Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].

Merkesdal S, Ruof J.

Z Rheumatol. 2002;61 Suppl 2:II/29-32. Review. German.

PMID:
12491120
16.

Ankylosing spondylitis: what is the cost to society, and can it be reduced?

Boonen A, Severens JL.

Best Pract Res Clin Rheumatol. 2002 Sep;16(4):691-705. Review.

PMID:
12406435
17.

Economic considerations of the treatment of ankylosing spondylitis.

Reveille JD, Ximenes A, Ward MM.

Am J Med Sci. 2012 May;343(5):371-4. doi: 10.1097/MAJ.0b013e3182514093. Review.

18.

Baseline predictors of response to TNF-α blocking therapy in ankylosing spondylitis.

Arends S, van der Veer E, Kallenberg CG, Brouwer E, Spoorenberg A.

Curr Opin Rheumatol. 2012 May;24(3):290-8. doi: 10.1097/BOR.0b013e32835257c5. Review.

PMID:
22418743
19.

[Anti-TNF alfa therapy in ankylosing spondylitis].

Cravo AR, Tavares V, Da Silva JC.

Acta Med Port. 2006 Mar-Apr;19(2):141-50. Epub 2006 Aug 18. Review. Portuguese.

20.

[The role of biologic agents in the therapy of ankylosing spondylitis].

Géher P, Nagy MB, Péntek M, Tóth E, Brodszky V, Gulácsi L.

Orv Hetil. 2006 Jul 2;147(26):1203-13. Review. Hungarian.

PMID:
16898082
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk